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ABSTRACT: Brucellosis is endemic in free-ranging elk (Cervus elaphus) and bison (Bison bison)
in the Greater Yellowstone Area (GYA; USA). It is possible that an oral brucellosis vaccine could
be developed and disseminated in the GYA to reduce disease transmission. Should this occur,
non-target species other than elk and bison may come in contact with the vaccine resulting in
morbidity or mortality. To assess biosafety, bighorn sheep (Ovis canadensis; n510), pronghorn
(Antilocapra americana; n59), mule deer (Odocoileus hemionus; n511), moose (Alces alces shir-
asi; n510), and coyotes (Canis latrans; n524) were given a single oral dose of at least 1.031010
colony-forming units of Brucella abortus strain RB51 vaccine (RB51). Animals were randomly
divided into vaccinated and control groups. Ungulates were captured, blood sampled, and swabs
taken from the nares, rectum, and vagina for bacterial culture on day 0, 42, and 84 post-inocu-
lation (PI). On day 42, the vaccinated group became a control group and vice versa in a crossover
design. Blood and swab samples were taken from coyotes on days 0, 14, 28, and 42 PI. There
was no crossover for the coyote study. Two coyotes from each group were also euthanized and
cultured for RB51 on days 42, 84, 168, and 336 PI. Blood samples were analyzed for hematologic
changes and antibodies to RB51 using a modified dot-blot assay. No morbidity or mortality as a
result of vaccination was observed in any animal. There were no differences in hematologic
parameters at any time for ungulate species; vaccinated coyotes had higher hematocrit, hemoglo-
bin, and eosinophil counts (P#0.006). All individuals, except some moose, seroconverted to RB51.
Strain RB51 was cultured from oropharyngeal lymph nodes from one coyote 42 days PI and from
a moose 117 days PI. This study suggested that a single oral dose of RB51 was safe in these
species.
Key words: Alces alces, Antilocapra americana, bighorn sheep, Brucella abortus, Canis la-
trans, coyote, moose, mule deer, Odocoileus hemionus, Ovis canadensis, pronghorn, strain RB51,
vaccination.
INTRODUCTION
Brucellosis is a zoonotic disease causing
abortion in domestic and wild ungulates
and undulant fever in humans (Hunter
and Kreeger, 1998). A federal/state Co-
operative Brucellosis Eradication Program
began in 1934 with the goal of eliminating
brucellosis in cattle from the United
States. This goal is close to being accom-
plished (Cheville et al., 1998). However,
brucellosis is endemic in elk (Cervus ela-
phus) and bison (Bison bison) in the
Greater Yellowstone Area (GYA), an eco-
system encompassing Yellowstone and
Grand Teton National Parks and surround-
ing areas in Wyoming, Montana, and Ida-
ho (Tunnicliff and Marsh, 1935).
Brucellosis can be controlled through
vaccination (Cheville et al., 1998). Brucel-
losis vaccines are comprised of living, mu-
tant Brucella organisms that infect the host
and induce protective immunity, but are
less pathogenic than the parent strains.
Two licensed brucellosis vaccines are B.
abortus strain 19 and RB51. Strain 19 has
been used for decades in cattle and free-
ranging elk (Herriges et al., 1989). How-
ever, strain 19 induces production of an-
tibodies to the lipopolysaccharide (LPS)
O-side chain of B. abortus that are de-
tected in most brucellosis serologic tests
(Stevens et al., 1995) which makes differ-
entiation between infection and vaccina-
tion difficult. Strain RB51 is a laboratory-
derived rough mutant of virulent B. abor-
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tus strain 2308 that lacks most of the an-
tigenic LPS O-side chain (Schurig et al.,
1991). Because RB51 does not induce pos-
itive responses on brucellosis serologic
tests (Stevens et al., 1994), it has become
the preferred vaccine for cattle and it may
become the preferred vaccine for wildlife.
Currently, several thousand elk are vac-
cinated annually by the Wyoming Game
and Fish Department with strain 19 as
they congregate on winter feedgrounds (S.
Smith, unpubl. data). Vaccine is delivered
via a biodegradable ballistic implant or
‘‘biobullet’’ (Herriges et al., 1989). How-
ever, ballistic delivery may limit wide-
spread application to free-ranging animals.
Animals not on feedgrounds could be vac-
cinated if an oral vaccine was developed
and deployed. Oral delivery of RB51 has
been investigated and results indicated
that this could be a safe and efficacious
route (Elzer et al., 1998).
If an oral brucellosis vaccine were dis-
seminated in bait in the GYA, species oth-
er than elk and bison would probably con-
sume the vaccine. Non-target species
could also be exposed to the vaccine by
contacting abortions from vaccinated
dams. It is important for wildlife managers
to evaluate the safety of such vaccines in
these non-target species. Herein, we re-
port on the safety of a single oral dose of
RB51 in bighorn sheep (Ovis canadensis),
pronghorn (Antilocapra americana), mule
deer (Odocoileus hemionus), moose (Alces
alces), and coyotes (Canis latrans).
MATERIALS AND METHODS
The ungulate study took place from Novem-
ber 1997 to February 1999 at the Wyoming
Game and Fish Department’s Sybille Wildlife
Research and Conservation Education Unit (Sy-
bille), Wheatland, Wyoming (USA, 4184597780N,
10582296050W). The coyote study took place
from May 1998 to May 1999 at the National
Wildlife Research Center (NWRC), Logan,
Utah (USA, 4183990000N, 105811193000W). The
following adult animals were used in the study:
10 Shira’s moose (two males, eight females), 10
Rocky Mountain bighorn sheep (one male, nine
females), nine pronghorn (four males, five fe-
males), 11 mule deer (seven males, four fe-
males), and 24 coyotes (16 males, eight fe-
males). Pronghorn and sheep were residents at
Sybille; the moose and mule deer were cap-
tured in Wyoming via chemical immobilization
and transported to Sybille. Moose were housed
in large 90-ha semi-natural enclosures; other
ungulates were housed in 0.5 ha pens. All un-
gulates were fed alfalfa hay supplemented with
a high-energy pelleted supplement. Water and
a trace mineral block were provided ad libitum.
Coyotes were residents at the NWRC and
housed in 1.233.7 m pens. Coyotes were fed a
commercial canine diet (Mazuri Feeds, Purina
Mills, Inc., St. Louis, Missouri, USA).
The experimental design was the same for all
ungulate species. Animals were randomly and
equally divided into vaccinated and control
groups. On day 0 of an experiment, animals
were captured (chemically or physically), blood
sampled, and swabs taken from the nares, rec-
tum, and vagina for bacterial culture. Swabs
were placed on ice for transport and cultured
(Alton et al., 1988) within 24 hr of sampling.
The vaccinated group was given a single
standard cattle dose of RB51 orally. This was
accomplished by reconstituting commercial
vaccine (Colorado Serum Co., Denver, Colo-
rado, USA) and injecting 2 ml of the vaccine
into the buccal cavity via syringe. The cheek
was then rubbed for about 1 min against the
molars to excoriate the mucosa to enhance vac-
cine uptake. The vaccine was sampled for po-
tency on the day of vaccination (Alton et al.,
1988). The control group was treated similarly
except given only physiologic saline.
On day 42, ungulates were again captured,
blood sampled, and cultured as before. Animals
in the previous vaccinated group then became
the new control group and animals in the pre-
vious control group were given oral RB51 vac-
cine and became the new vaccinated group in
a crossover design. Vaccine was again sampled
for potency. On day 84, animals were recap-
tured, blood sampled, and cultured as before.
All animals were observed daily for morbidity
or mortality during the test and monitored for
several months thereafter.
Coyotes were randomly (except for sex) and
evenly divided into a vaccinated (eight males,
four females) and a control group (eight males,
four females). The control group received sa-
line orally. Blood and swab samples were taken
as for ungulates except samples were taken on
days 0, 14, 28, and 42 post-inoculation (PI).
There was no crossover for the coyote study.
Two coyotes from each group were eutha-
nized and cultured for RB51 on days 42, 84,
168, and 336 PI as part of this study. Of the
ungulates, only moose were euthanized at the
end of the study (day 84) secondary to man-
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agement considerations and other research. If
any other ungulate died, it was subjected to a
full necropsy with selected tissues cultured for
Brucella. Aseptic techniques were used to col-
lect the following tissues: mandibular, medial
and lateral retropharyngeal, parotid, prescapu-
lar, prefemoral, external and internal iliac, pop-
liteal, mediastinal, mesenteric, hepatic, supra-
mammary and bronchial lymph nodes; mam-
mary gland; uterus; cervix; ovaries; testes; kid-
ney; biceps femoris; spleen; and liver. When
applicable, both paired structures were collect-
ed. Tissue samples were macerated, cultured
(Alton et al., 1988), and bacterial isolates iden-
tified (Quinn et al., 1994).
Blood samples were analyzed for hematolog-
ic changes (Schalm et al., 1975) and antibodies
to RB51 using a modified dot-blot assay (Kree-
ger et al., 2000). For ungulates, differences in
hematologic parameters and RB51 antibody ti-
ters (unvaccinated versus 42 days post-vacci-
nation only) between vaccinated and control
groups were compared by one-way ANOVA at
a significance level of P#0.05. If there were no
differences between groups at day 42, then the
vaccinated group was considered a suitable
control group for the crossover design. If there
were differences at day 42, then groups were
compared only for the initial 6 wk period. For
coyotes, differences in parameters between
groups were compared by ANOVA for repeated
measures at a significance level of P#0.05.
Means are reported with standard errors.
RESULTS
On day 0, the vaccinated groups of big-
horn sheep, pronghorn, and mule deer re-
ceived 2.031010 colony-forming units
(CFU) RB51; on day 42, the vaccinated
groups were given 1.431010 CFU RB51.
No bighorn sheep or pronghorn died dur-
ing the study, nor was any morbidity ob-
served. However, three mule deer (two
male, one female) vaccinated on day 0
died between 6–12 wk PI. No Brucella
were cultured from any tissues. Two of the
three deaths were diagnosed as pneumo-
nia; the other cause of death was undeter-
mined. There were no differences in he-
matologic parameters between any of the
groups at any time (P$0.14). No swab cul-
tures analyzed for RB51 shedding resulted
in growth of Brucella for any of the
groups. All bighorn sheep, pronghorn, and
mule deer seroconverted post-vaccination
(P#0.017; Table 1).
The moose study was started a few
weeks after the other ungulate groups. On
day 0, the vaccinated group received
1.031010 CFU RB51; on day 42, the vac-
cinated group was given 8.03109 CFU
RB51. No morbidity was observed during
the study. One unvaccinated bull died
from acute pneumonia 1 day after han-
dling. There were no differences in he-
matologic parameters between groups at
any time (P$0.46). No swab cultures re-
sulted in growth of Brucella. All female
moose were eventually euthanized several
weeks after termination of the study. One
cow, euthanized 117 days PI, was culture
positive for RB51 in the parotid, retropha-
ryngeal, and submandibular lymph nodes.
Not all moose seroconverted (P50.07; Ta-
ble 1).
On day 0, vaccinated coyotes received
1.031010 CFU RB51. No morbidity or
mortality was observed during the study.
During week 6 of the study, vaccinated
coyotes had higher hematocrit (P50.007),
hemoglobin (P50.006), and eosinophil
(P50.0001) values than did controls; how-
ever, all hematologic values were within
the range of normal values established for
coyotes at this facility (T. Deliberto, un-
publ. data). All vaccinated coyotes sero-
converted to RB51 (P#0.05; Table 2). No
swabs were culture positive for B. abortus.
One male, euthanized 42 days PI, was cul-
ture positive for RB51 in the parotid, sub-
mandibular, and medial retropharyngeal
lymph nodes. Strain RB51 was not cul-
tured from any other tissues at any time.
DISCUSSION
This study demonstrated that oral in-
oculation of RB51 resulted in infection
and, thus, seroconversion in these species.
The results also suggested that RB51 was
neither shed during the period of this
study nor resulted in clinical disease in
these species, including moose. Other than
moose, these results were anticipated be-
cause there was no evidence that the more
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virulent field strain B. abortus was a sig-
nificant pathogen of bighorn sheep, prong-
horn, mule deer, or coyote.
In Arizona (USA) and Alberta (Canada),
52 bighorn sheep were tested for B. abor-
tus antibodies and none were found posi-
tive (Zarnke and Yuill, 1981; Davis, 1990).
Pronghorn also do not appear to be sus-
ceptible to brucellosis. Only one of 6,046
pronghorn from Colorado, Wyoming,
North Dakota, Arizona, Idaho, Nebraska,
Alberta, and Saskatchewan had antibodies
against B. abortus (Adrian and Keiss, 1977;
Davis, 1990). Mule and white-tailed deer
(Odocoileus virginianus) have been inten-
sively surveyed. Only 46 of .25,000 deer
in 29 states reacted positively on a variety
of serologic tests (Davis, 1990).
Moose, however, have long been
thought to be highly susceptible to bru-
cellosis. Brucella abortus was isolated from
moribund moose in Minnesota (Fenster-
macher and Olson, 1942) and Montana
(Jellison et al., 1953) and two sick moose
from Alberta were highly seropositive
(Corner and Connell, 1958). Serologic ev-
idence of brucellosis was found in nine of
44 moose in Montana (Jellison et al.,
1953), 0 of 124 moose in Alberta, 0 of 104
moose in British Columbia (Canada; Cor-
ner and Connell, 1958), 0 of 44 moose in
Alberta (Zarnke and Yuill, 1981), one of 39
moose in Alaska (Zarnke, 1983), and 0 of
208 moose from Quebec (Canada; Bo-
urque and Higgins, 1984). Low seroposi-
tivity in these surveys plus observed mor-
bidity suggested that brucellosis in moose
was usually fatal (Thorne et al., 1978). In
this study, RB51 infected moose but
caused no morbidity. This lack of patho-
genicity could be due to either a low in-
oculation dose or reduced virulence of
RB51 (Palmer et al., 1996).
Coyotes can become infected with B.
abortus in the wild (Davis et al., 1979) and
can transmit brucellosis to cattle under ar-
tificial conditions (Davis et al., 1988).
Transmission to cattle was thought to have
occurred by coyotes shedding organisms in
feces. Domestic canids can shed Brucella
in uterine discharges, urine, and feces
(Morse et al., 1951). However, we did not
detect coyotes shedding RB51 in this
study.
The coyote results were consistent with
a previous study where beagles were orally
inoculated with a single, higher dose (1012
CFU) of RB51 (Palmer and Cheville,
1997). Beagles did not show clinical signs
after inoculation nor was shedding ob-
served. Oropharyngeal lymph nodes were
culture positive in beagles necropsied 49
days PI. No coyotes in this study were
pregnant, but oral RB51 did not cause
abortion in pregnant beagles, although
placentitis was observed (Palmer and Che-
ville, 1997).
Differences in hematologic parameters
between vaccinates and control coyotes
cannot be explained at this time. It is un-
known how or why infection with RB51
could affect these values, particularly red
blood cell indices. Since all coyotes were
housed and fed similarly, it is not thought
that husbandry practices caused these re-
sults. Although these differences were sta-
tistically significant, these parameters are
within normal ranges for coyotes and they
are not thought to be biologically signifi-
cant.
A single oral inoculation of RB51 was
safe in bighorn sheep, pronghorn, mule
deer, moose, and coyotes. It would have
been valuable to assess multiple doses be-
cause this may occur in the field. However,
it is difficult to obtain these species for re-
search, particularly moose and bighorn
sheep, and they are expensive to maintain.
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